The important question around this product comparison is practical: what is actually known, what remains uncertain, and what safeguards a licensed clinician and pharmacy process add before anyone treats it as an option.
A friend of mine, an internist in Dallas, told me about a patient last fall who came in with a printed spreadsheet. Three columns: Wegovy at her local Walgreens ($1,287 cash), a compounded semaglutide program she found online ($199/month), and a med spa offering “GLP-1 shots” at $450 per injection with no lab work required. She wanted to know which column to trust. My friend said the conversation took 45 minutes, which is about 42 minutes longer than most office visits allow. That gap between what patients can find and what they actually understand is the reason this article exists.
So let’s get the core distinction right up front. Compounded semaglutide is the same active pharmaceutical ingredient found in Ozempic and Wegovy. It’s prepared by a state-licensed or 503A compounding pharmacy for an individual patient under a clinician’s prescription. It is not an FDA-approved finished product. The pharmacology is the same. The regulatory pathway is not. Collapsing those two facts into “it’s basically generic Ozempic” or “it’s unregulated garbage” are both wrong, and both are popular online.
The Molecule vs. the Supply Chain
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk, approved as Ozempic in 2017 for type 2 diabetes and as Wegovy in 2021 for chronic weight management. What it does is fairly elegant: it mimics an incretin hormone your gut already makes, amplifying insulin secretion when blood sugar is elevated, suppressing glucagon after meals, slowing gastric emptying, and (this is the part people care most about) dialing down appetite through hypothalamic signaling. The long half-life means once-weekly dosing works.
The compounded version contains the same molecule. The difference is manufacturing scale, regulatory classification, and post-market surveillance infrastructure. Compounded preparations fall under section 503A of the Federal Food, Drug, and Cosmetic Act and parallel state pharmacy regulations. This framework is well established across many drug classes; compounding isn’t some rogue corner of pharmacy. But it is a different framework, and pretending otherwise doesn’t help anyone.
What the Clinical Trials Actually Show
The evidence base for semaglutide as a weight-loss agent comes primarily from the STEP program, and it’s worth knowing what those trials measured and in whom.
STEP-1 randomized 1,961 adults with overweight or obesity (no diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks, with lifestyle intervention in both arms. The semaglutide group lost approximately 14.9% of body weight versus 2.4% in the placebo group (Wilding et al., New England Journal of Medicine, 2021). Those are means, though. Individual responders ranged widely: some lost 5%, others lost north of 20%. STEP-3 layered on intensive behavioral therapy and pushed the numbers slightly higher. STEP-5 extended follow-up to 104 weeks and showed the weight reduction held in the active arm.
On the diabetes side, the SUSTAIN program established the glycemic and cardiovascular profile at lower doses (0.5 mg and 1.0 mg weekly, with 2.0 mg added later in SUSTAIN FORTE). The cardiovascular outcome trial, SUSTAIN-6 (Marso et al.), reported a reduction in the composite of major adverse cardiovascular events in high-risk diabetes patients.
Here’s the honest part: every bit of this data was generated using the brand-name finished product. It informs our understanding of what the molecule does, but the compounded preparations have not been studied as finished products in registrational trials. That’s not a reason to dismiss compounded semaglutide. It is a reason to understand what we’re extrapolating from.
Titration, Dosing, and the Details That Actually Matter Day to Day
The standard titration from the STEP trials (and the Wegovy label) is a five-step escalation: 0.25 mg for four weeks, 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, then 2.4 mg as maintenance. Full escalation takes roughly sixteen weeks.
Most compounded programs follow the same milligram schedule. Where things can get confusing is concentration. The dose that matters is the milligram dose, not the volume of liquid in the syringe. A compounded vial at 5 mg/mL requires a different draw volume than one at 2.5 mg/mL for the same clinical dose. Patients switching between programs (or pharmacies within a program) should confirm milligrams at every step. This sounds basic. It gets missed.
The schedule is flexible. A patient nauseated at 0.5 mg can sit at that dose for an extra four weeks. A patient responding well at 1.7 mg can stay there indefinitely rather than pushing to 2.4 mg. The titration is a clinical decision, not a checklist.
Storage: refrigerate at 36 to 46°F, with limited room-temperature time acceptable for transport. Injection-site rotation between abdomen, thigh, and upper arm reduces local irritation. These are small operational things, but they shape the daily experience more than most clinical papers acknowledge.
Side Effects: Predictable, Manageable, Occasionally Serious
GI side effects dominate. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. Across STEP and SUSTAIN, these were mostly mild to moderate, concentrated in the first eight to twelve weeks, and resolved with continued therapy or temporary dose adjustment. If you’ve talked to anyone on semaglutide, you’ve heard the nausea stories. They’re real, and for most people, they’re temporary.
Less common but clinically important: gallbladder events (especially with rapid weight loss), acute pancreatitis (rare, but requires immediate evaluation if someone develops severe abdominal pain radiating to the back), and a thyroid C-cell tumor signal from rodent studies that has not been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning on the thyroid finding and a contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Hypoglycemia on semaglutide alone in non-diabetic patients is uncommon because the insulin effect is glucose-dependent. The risk climbs when it’s combined with insulin or sulfonylureas, and in that setting, the other agent’s dose typically needs adjustment.
My honest take: the side-effect profile is well characterized and manageable for most patients when the titration is done properly. The programs that create problems are the ones that skip steps, rush to high doses, or don’t have a clinician actually available when a patient calls with persistent vomiting.
Cost, Access, and Why the Price Gap Exists
Brand-name Wegovy and Ozempic list north of $1,300 per month. Cash-pay rates at most retail pharmacies land between $1,000 and $1,400. Insurance coverage for weight management indications remains inconsistent (the diabetes indication fares better, but plan-to-plan variation is significant).
Compounded semaglutide programs in compliant telehealth structures price substantially lower. HealthRX, for example, runs $179.99 to $279.99 per month depending on dose, is available in 44 US states, and operates under LegitScript certification.
The pricing gap is structural, not suspicious. Brand-name products carry the full cost of industrial-scale manufacturing, regulatory submissions, post-marketing surveillance, and the commercial margin that funds next-generation R&D. Compounded preparations are produced at a different scale through a different regulatory pathway. Different cost structure, different price.
HSA and FSA reimbursement depends on your specific plan and the documentation format the program provides. Worth confirming before you enroll, not after.
Compounded vs. Brand-Name: What the Distinction Actually Means
This comparison gets flattened into marketing copy constantly, so let me be specific about the three practical differences.
First, the clinical evidence base from STEP and SUSTAIN was built on the brand-name finished product. The pharmacology of the molecule is the same, but the data doesn’t directly extend to compounded preparations as studied finished products.
Second, manufacturing oversight differs. Compounded pharmacies are regulated by state boards of pharmacy (and, for 503B outsourcing facilities, by the FDA under a separate framework). Brand-name manufacturers operate under the full FDA finished-product regulatory apparatus.
Third, the adverse-event reporting system is less complete for compounded preparations.
None of this means compounded semaglutide is inherently inferior or unsafe. It means the two pathways operate in different regulatory and evidentiary frames, and a patient who understands those differences is better positioned to make a decision that fits their situation. Patients who want a fuller framing can read this product comparison, which covers the clinical and practical questions that come up in a real intake conversation. It’s useful background reading, not a substitute for a clinical conversation with your own provider.
When You Should Pick Up the Phone
Some situations call for contacting your prescribing clinician rather than waiting for your next check-in:
Persistent severe abdominal pain, particularly radiating to the back or accompanied by fever. Inability to keep fluids down for more than 24 hours, signs of dehydration, or persistent vomiting. New gallbladder symptoms (right upper quadrant pain after meals, jaundice). Reflux that doesn’t respond to meal-timing adjustments. New or worsening mood changes, including depressive symptoms.
Pregnancy, planned pregnancy, or breastfeeding: talk to your clinician before the next dose, not after. Personal or family history of medullary thyroid carcinoma or MEN2 should have been surfaced at intake. If it wasn’t, raise it now.
Patients on insulin, sulfonylureas, or other glucose-lowering agents who notice hypoglycemic episodes need dose adjustment of the concurrent therapy. Patients on warfarin or other narrow-therapeutic-window medications should discuss whether semaglutide’s slowed gastric emptying affects absorption of those drugs.
Frequently Asked Questions
Is compounded semaglutide the same drug as Ozempic and Wegovy? The active ingredient, semaglutide, is the same. The finished product, regulatory category, and manufacturing pathway are different. Ozempic and Wegovy are FDA-approved finished products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.
How long does treatment typically last? STEP-1 captured 68 weeks, STEP-5 extended to 104 weeks, and clinical experience now exceeds two years. Duration is individualized based on the patient’s goals, response, and tolerability.
Is the weight reduction sustained after stopping? STEP-4 showed significant regain in participants switched to placebo after a lead-in period, suggesting the metabolic effect depends on continued therapy for many patients. Long-term outcomes after discontinuation hinge on the lifestyle changes consolidated during treatment.
Do I need labs to start? A careful program will document baseline labs, typically including a metabolic panel, lipid panel, A1c, and sometimes a thyroid panel. The specific panel depends on your clinical picture.
Is semaglutide right for everyone? No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A thorough intake conversation should surface these before therapy begins.
What if I experience side effects during titration? The appropriate response is usually to hold at the current dose for an additional four weeks or to temporarily reduce. Severe or persistent symptoms warrant direct contact with your prescribing clinician.
Can I switch from brand-name to compounded semaglutide (or vice versa)? Yes, provided you confirm the milligram dose at each step. The transition is straightforward clinically; the key is continuity of dosing and clinical oversight.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
